Beyond glucose: cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates
نویسندگان
چکیده
منابع مشابه
Diabetes and cardiovascular risk: are dipeptidyl peptidase-4 inhibitors beneficial?
Cardiovascular (CV) disease is a major cause of morbidity and mortality in patients with diabetes. Whereas the link between glycemic control and reducing microvascular disease is firmly established, the evidence for macrovascular risk reduction remains unclear. Despite a host of available drugs for lowering serum glucose, none to date have been shown to substantially reduce CV risk and some hav...
متن کاملRegulation of dipeptidyl peptidase 4 production in adipocytes by glucose
OBJECTIVE Type 1 and 2 diabetes are characterized by elevated blood glucose levels and increased dipeptidyl peptidase 4 (DPP4) activity levels in the serum. However, previous studies reported a negative correlation between glucose concentrations and DPP4 levels. The purpose of this study was to elucidate the connection between glucose and DPP4 in adipocytes under physiological and diabetic cond...
متن کاملDipeptidyl Peptidase-4 Inhibitor
In the United States, nearly 13% of adults aged 20 years and older have type 2 diabetes mellitus (T2DM), and its prevalence is still increasing (1,2). Microvascular and macrovascular abnormalities are common in patients with T2DM and are related to the severity and duration of hyperglycemia (3–5). Thus, treatment of hyperglycemia is an important way to prevent or delay diabetic vascular complic...
متن کاملIncretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.
Type 2 diabetes mellitus is the most outspreading disease of the western world and it provides cardiovascular disease. During the past decade new drug categories were added to the already existing ones. Perhaps, the most outstanding, as promising, too, are glucagon-like peptide-1(GLP-1) analogues, which pinpointed at the incretin hormone system, targeting mainly at the postprandial hyperglycemi...
متن کاملDipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Dipeptidyl peptidases 4 (DPP4) inhibitors are a new class of oral anti-hyperglycemic drugs for the treatment of type 2 diabetes (T2DM). They are also called "incretins" because they act by inhibiting the degradation of endogenous incretin hormones, in particular GLP-1, that mediates their main metabolic effects. DPP4 is an ubiquitous protease that regulates not only glucose and lipid metabolism...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal Supplements
سال: 2012
ISSN: 1520-765X
DOI: 10.1093/eurheartj/sus001